PrintBio
ApplicationLong Island City, USAFounded 2019
Developing 3D-bioprinted living implants and resorbable surgical meshes to repair or replace damaged human tissues.
- CEO / Founder
- Kevin Slawin
- Team Size
- 10-50
- Stage
- Commercial and Clinical stage
- Total Funding
- $31.4M
- Latest Round
- Series A
- Key Investors
- ["Rapha Capital Management","Aurum Venture Partners","Expa","Network VC"]
Technology & Products
Key Products
["3DMatrix™","3DMatrix DynaFlex™","DynaForm™","GMPrint™","Vascularized Kidney Tissue"]
Technological Advantage
Proprietary end-to-end biofabrication pipeline including GMPrint™ and Uniflex™ technology.
Market & Competition
Target Customers
Surgeons, hospitals, federal health agencies
Industry Verticals
["Biotechnology","Regenerative Medicine","Medical Devices"]
Competitors
["3DBio Therapeutics","TELA Bio","Organovo","BICO"]